Early Pharmacological and Immune Monitoring After Conversion to Belatacept in Renal Transplant Patients

Launched by UNIVERSITY HOSPITAL, TOURS · Nov 18, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how well a medication called belatacept works for patients who have received a kidney transplant. Specifically, it focuses on patients who are switching from another type of medication to belatacept. Researchers want to understand how this change affects the patients' immune responses and overall health. The study is currently recruiting participants who are at least 18 years old, have had a kidney transplant, and are making this switch in their medication.

If you or a loved one is considering participating, it's important to know that some people may not be eligible, such as those with very low hemoglobin levels, pregnant or breastfeeding women, or those who do not agree to the processing of their data. Participants can expect to be closely monitored throughout the study to ensure their safety and to gather important information about how well belatacept works in this setting. This research aims to improve care for kidney transplant patients by understanding the best ways to manage their medications.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Renal transplant patient
• • Patient converted from an anticalcineurin to belatacept
• Exclusion Criteria:
• • Opposition to data processing
• • Hemoglobin \< 9g/dL
• • Patient under judicial protection
• • Pregnant or breastfeeding woman